Dipexium shares eviscerated after lead antibiotic flops on a full slate of PhIII endpoints
The microcap biotech Dipexium Pharmaceuticals $DPRX went public in 2014, promising to advance an important new antibiotic cream in the clinic. But today, the little biotech was forced to concede that their lead program flopped badly in two late-stage studies, flunking the primary as well as secondary endpoints.
Not only was there no “meaningful difference” between their antibiotic and standard care for wound closure rates among patients with diabetic foot ulcers, it also wasn’t able to eradicate bacteria significantly better. Adding insult to injury, the company added that “serious adverse events with Locilex included higher than anticipated osteomyelitis and cellulitis in the Locilex arm of each study.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
